The history of antibody research and development dates back to the late 19th century, when the German scientist Emil von Behring discovered that serum from an animal previously infected with diphtheria could be used to prevent the disease.
Since then, the study of antibodies has led to significant advancements in our understanding of the immune system and the development of treatments for a wide range of diseases. In the early 1970s, the hybridoma technology was developed, which allowed for the production of monoclonal antibodies (mAbs) – antibodies that are identical and specific to a single antigen. This technology revolutionized the field of antibody research and led to the development of many life-saving drugs.
More recently, the field of recombinant antibody technology has emerged, which allows for the production of fully human antibodies in large quantities. These antibodies are generated by combining a human antibody gene with a host cell, such as Chinese hamster ovary (CHO) cells, to create a recombinant cell line. Recombinant antibody technology has become a powerful tool in drug discovery and development, allowing for the rapid production of high-quality, fully human antibodies for use in therapeutic applications.
At Biointron, we specialize in the production of high-quality recombinant antibodies for use in drug discovery and development. Our state-of-the-art platform enables the rapid expression of a large number of antibodies in CHO cells, with amounts guaranteed from 100ug to 100g. With our technology, we can deliver fully human antibodies in just two weeks from gene synthesis to purified antibody. Contact us to learn more about our recombinant antibody services and how we can support your drug discovery efforts.
Biointron’s AbDrop & Cyagen’s HUGO-Ab is a high-throughput fully human antibody discovery platform that combines microdroplet-based single B cell screening with transgenic mice. This combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months.
The development of chimeric antibodies was a significant turning point in antibody engineering. To engineer more human-like antibodies, researchers combined the variable regions of antibodies from one species with the constant regions of another, resulting in increased antigen specificity with reduced immunogenicity. This was a key advance in making antibodies more suitable for therapeutic applications in humans.
DOI:10.1016/j.trecan.2024.07.002Bispecific antibodies (bsAbs) are a class of engineered therapeutic molecules designed to engage two different epitopes or antigens simultaneously, providing them with unique functionalities that go beyond traditional monoclonal antibodies. By targeting two distinct a
The 22nd Annual Discovery on Target 2024 was held in Boston, MA on September 30 to October 3, 2024. This four-day event involved discussion on popular topics like kinases, immunomodulation, and degraders, plus coverage of covalent chemistries and induced proximity, synthetic biology, cancer antibodies, generative AI, and translational models.
